Imaging changes in synaptic acetylcholine availability in living human subjects

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 78-82

  Esterlis, Irina ^a   Hannestad, Jonas O ^a   Bois, Frederic ^a   Sewell, R Andrew ^a   Tyndale, Rachel F ^b   Seibyl, John P ^c   Picciotto, Marina R ^a   Laruelle, Marc ^a   Carson, Richard E ^a   Cosgrove, Kelly P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

nAChRs; Extracellular acetylcholine; Physostigmine

Indexed keywords

IODINE 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; NICOTINIC RECEPTOR BETA2; PHYSOSTIGMINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN REGION; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

EID: 84872047034     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.111922     Document Type: Article

References (19)

1. 2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry. 2012;169:851-859.
2. Abreo MA, Lin N-H, Garvey D, et al. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem. 1996;39:817-825.
3. 125I]5-IA 85380, a nicotinic acetylcholine receptor radioligand. Neuroreport. 1998;9:2311-2317.
4. Mukhin AG, Gundisch D, Horti A, et al. 5-iodo-A-85830, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol. 2000;57:642-649.
5. 123I]5-I-A85830 SPECT. J Nucl Med. 2000;41:1552-1560.
6. 123I]iodo-A-85830 using single photon emission computed tomography. Life Sci. 1998;63:PL355-PL360.
7. Staley JK, van Dyck CH, Weinzimmer D, et al. Iodine-123-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. J NuclMed. 2005;46:1466-1472.
8. 123I]5-I-A-85830 in healthy human subjects. Eur J Nucl Med Mol Imaging. 2002;29:183-190.
9. 18F]fluoro-A-85380: a PET study in monkeys. Synapse. 2005;56:217-221.
10. 123I]5-I-A-85380. Synapse. 2003;48:116-122.
11. Noori HR, Fliegel S, Brand I, Spanagel R. The impact of acetylcholinesterase inhibitors on the extracellular acetylcholine concentrations in the adult rat brain: a meta-analysis. Synapse. 2012;66:893-901.
12. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
13. Beck AT, Ward C, Mendelsohn M, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
14. Spielberger C, Corsuch R, eds. Manual for state-trait anxiety inventory. Palo Alto CA: Consulting Psychologists Press; 1983.
15. Esterlis I, Cosgrove K, Batis J, et al. Quantification of smoking induced occupancy of β2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med. 2010;51:1226-1233.
16. Esterlis I, Mitsis E, Batis J, et al. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14:389-398.
17. D'Souza DC, Esterlis I, Carbuto M, et al. Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry. 2012;169:326-334.
18. 18F]fluoro-A-85380 PET study. Neurobiol Learn Mem. 2008;90:404-412.
19. Brody AL, Mandelkern M, Costello M, et al. Brain nicotinic cetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12:305-316.